Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1969)	10/15/2007 10:39:04 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

IMMU has formed a base at the $2.25 level & is up 15% today. bigcharts.marketwatch.com No special news that I am aware. Today's volume is already close to its ADV. With some good news it seems that the stock could get back to the $5 level.<g> bigcharts.marketwatch.com In July it was reported that Epratuzumab preferentially modulates the exaggerated activation and proliferation of B cells from SLE patients in contrast to normal subjects, suggesting that it might offer a new therapeutic option for patients with SLE, since enhanced B-cell activation is a hallmark of the disease. In Sep 2006 UCB put a hold on epratuzumab production because of concerns about sterility in its manufacturing. Bernard

To: Jibacoa who wrote (1969)	10/15/2007 10:49:57 AM
From: mopgcw	Read Replies (1) \| Respond to of 3722

it hit barron's this weekend...

To: Jibacoa who wrote (1969)	1/10/2008 12:00:09 AM
From: Jibacoa	Respond to of 3722

VIAP Closed up 10.7% as it traded above its Nov-Dec Hs. It closed at its intraday H & was up for 5th day on a roll. The volume remained low at only 11,254 <g> bigcharts.marketwatch.com It announced on Monday that it had enrolled the first patient in its PII that utilizes Positron Emission Tomography with fluorodeoxyglucose tracer to measure VIA-2291's ability to reduce vascular inflammation in treated patients. It also provided an update of the VIA-2291 PII. Although the "target" for VIAP is still around $7. if the stock could retest its Oct10 H at $5.30 it would be a good % gain from present levels.<g> bigcharts.marketwatch.com Bernard